Back to search

Boston University

Osteosarcoma: molecular etiology, pathophysiology, clinical presentation, diagnosis, and treatment

Abstract

dc:description.abstract

Osteosarcoma is the most common primary malignancy of bone in children and young adults, with a worldwide incidence of 3.4 cases per million people per year. For most of the 20th century — before the advent of chemotherapy — osteosarcoma was inevitably fatal. Despite effective local control achieved through highly invasive and ultimately disabling surgical procedures, the vast majority of patients developed pulmonary metastasis and most often died in a matter of months. Fortunately, treatment strategies have evolved tremendously to include multi-agent adjuvant chemotherapy and various forms of limb-sparing surgery that have largely taken the place of amputation. This transformation in therapeutic approach materialized gradually, and became firmly established in practice during the early 1990s. Not surprisingly, it was around that same time that a rather dramatic increase in five-year survival was noted in patients presenting with localized disease — jumping from less than 20% prior to the advent of chemotherapy, to 60-70% following implementation of the current standard of care. However, since this initial period of advancement, very little progress has been made. Systemic treatment strategies have barely evolved over the course of the past two decades, and the probability of long-term survival thus remains largely unchanged. While it is true that roughly two-thirds of patients with localized conventional osteosarcoma survive for at least 5 years after receiving multi-modal therapy, the following fact better reflects the highly-aggressive nature of the disease, and thus also provides a more realistic representation of the long-term prognostic implications with which its typically associated: the risk of recurrence and metastasis remains markedly elevated following complete eradication of the primary tumor. After undergoing surgical resection and multiple rounds of both neoadjuvant and postoperative chemotherapy, a significant quantity of patients thought to be cured see their malignancy recur, spread, and invade distant tissue — at which point, the probability of disease-free survival drops to well below 20%. Thus, the need for enhanced, more precisely-targeted mechanisms of treatment is indisputable. Accordingly, this work will provide an in-depth description of the molecular etiology, pathophysiology, clinical presentation, diagnosis, and treatment of osteosarcoma, while also exploring potentially promising novel therapies aimed to improve patient outcomes.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2018

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Sinatro, Alec
Advisor dc:contributor.advisor
  • Layne, Matthew D.

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/33042

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Sinatro, Alec. Osteosarcoma: molecular etiology, pathophysiology, clinical presentation, diagnosis, and treatment. masters thesis, Boston University, 2018. https://hdl.handle.net/2144/33042